63050-11-3

Basic information

• Product Name: Ethyl 2-(broMoMethyl)nicotinate
• Synonyms: Ethyl 2-(broMoMethyl)nicotinate;Ethyl 2-(bromomethyl)pyridine-3-carboxylate
• CAS NO: 63050-11-3
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 63050-11-3.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 2-(broMoMethyl)nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(broMoMethyl)nicotinate(63050-11-3)
• EPA Substance Registry System: Ethyl 2-(broMoMethyl)nicotinate(63050-11-3)

Safety Data

• Hazardous Substances Data: 63050-11-3(Hazardous Substances Data)

Usage

Description

Ethyl 2-(bromoMethyl)nicotinate is a chemical compound with the molecular formula C9H10BrNO2. It is a derivative of nicotinic acid and contains a bromomethyl group. Ethyl 2-(broMoMethyl)nicotinate is known for its ability to modify biological processes and has shown promising results in pre-clinical studies. Its unique structure and potential therapeutic benefits make it an interesting compound for further research and development.

Uses

Used in Pharmaceutical Industry:
Ethyl 2-(bromoMethyl)nicotinate is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a versatile building block for the development of new drugs.
Used in Anti-inflammatory Applications:
Ethyl 2-(bromoMethyl)nicotinate is used as an anti-inflammatory agent for its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Anti-cancer Applications:
Ethyl 2-(bromoMethyl)nicotinate is used as an anti-cancer agent for its potential to inhibit the growth and proliferation of cancer cells. Its biological activities have been studied, and it has shown promise in pre-clinical studies as a potential therapeutic agent for cancer treatment.
Used in Research and Development:
Ethyl 2-(bromoMethyl)nicotinate is used in research and development for its potential therapeutic benefits and unique structure. Further studies are being conducted to explore its full potential and develop new applications for this compound.

Upstream product

• 1721-26-2 ethyl 2-methyl nicotinate 
• 626-34-6 ethyl aminocrotonate 
• 13822-09-8 benzyl peroxide 

Downstream Products

• 5657-51-2 7H-furo[3,4-b]pyridin-5-one 
• 113301-83-0 ethyl 2-(phenoxymethyl)nicotinate 
• 165333-58-4 6-[(S)-1-benzyl-2-hydroxyethyl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one 
• 180161-81-3 6-(4-Chloro-phenyl)-6,7-dihydro-pyrrolo[3,4-b]pyridin-5-one 
• 209806-15-5 ethyl 2-(N-benzyl-N-phenylamino)methylnicotinate 
• 209806-22-4 (2-{2-[(benzyl-phenyl-amino)-methyl]-pyridin-3-yl}-2-oxo-ethyl)-phosphonic acid dimethyl ester 
• 209806-05-3 dimethyl 1-diazo-2-(2-(N-benzyl-N-phenylaminomethyl)pyridin-3-yl)-2-oxoethylphosphonate 
• 180161-82-4 [6-(4-Chloro-phenyl)-5-oxo-5,6-dihydro-pyrrolo[3,4-b]pyridin-(7E)-ylidene]-acetic acid 
• 180161-84-6 [6-(4-Chloro-phenyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl]-acetic acid 
• 180161-83-5 6-(4-Chloro-phenyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-7-carboxylic acid methyl ester 
• 1027181-73-2 C₂₀H₁₇ClN₂O₅ 
• 1026840-77-6 C₂₀H₁₉ClN₂O₅ 
• 1026646-35-4 6-(4-Chloro-phenyl)-7-ethoxycarbonylmethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-7-carboxylic acid methyl ester 

Relevant articles and documents

A cocktail of165Er(iii) and Gd(iii) complexes for quantitative detection of zinc using SPECT and MRI

We propose quantitative assessment of zinc by combining nuclear and MR imaging. We use a cocktail of a Gd3+-complex providing a Zn2+-dependent MRI response and its165Er3+ analogue allowing for concentration assessment.165Er is readily obtained in a cyclotron and purified, which is indispensable for successful quantification of metal ions.

HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST

A heterocyclic compound useful as an antiallergic agent is provided. A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R1 is a carbonyl group or an alkylene group; R2a and R2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R1 is an alkylene group which may have a substituent.

BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

A compound having the formula (1) wherein: Ra represents C1-6 alkyl, cyclobutyl or cyclopentyl; R1 represents H or C1-6 alkyl; R2 represents H or R1 and R2 together represent =0; X1 represents CR3 or N; X2 represents CR4 or N; X3 represents CR5 or N; X4 represents CR6 or N; wherein one or two of X1, X2, X3 and X4 represents N; R3, R4, R5 and R6 each independently represent H, C1-6 alkoxy or -NR7R8; R7 and R8 independently represent H or C1-6 alkyl; or R7 and R8 and the N atom to which they are attached are joined to form a N-containing heterocyclyl ring optionally substituted with one or more substituents independently selected from halogen, C1-6 alkyl and C1-6 alkoxy; or a pharmaceutically acceptable salt thereof, is provided. Compounds of the invention have been found to modulate the histamine H3 receptor.